AIM:To evaluate the effectiveness and safety of Conbercept for exudative age-related macular degeneration(eAMD)systematically, in order to provide evidence-based reference for clinical use.

METHODS:We performed a comprehensive search for the randomized controlled trials(RCTs)about conbercept trail group vs control group in the treatment of eAMD published by November, 2017 from PubMed, Cochrane Library, CNKI and Wanfang Database. Studies obtained from eligible database were filtered according to modified Jadad scale, and data were retrieved from those studies for further analysis. Then, we performed a Meta-analysis using RevMan 5.3 and Stata 12.0 statistical software.

RESULTS:A total of 12 RCTs were included, involving 924 patients. The results of Meta-analysis showed that the central macular retinal thickness(CMT)markedly decreased at 1, 3, 6 and 12mo after treatment; visual acuity at 3 and 6mo and quality of life(QOL)at 6mo were significantly improved; total effective rate of treatment at increased, which was statistically different to control group(P<0.05), but rate of adverse reaction was similar(P>0.05). The long-term effect was better than control group.

CONCLUSION:The existing evidence supports that conbercept has good therapeutic efficacy and safety for eAMD. It can significantly reduce the CMT, improve the visual acuity, the quality of life and the total efficiency of treatment, and the long-term effect is better than control group.